StemCell Therapy

In silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.

French in silico clinical trial specialist Novadiscovery said it will use the 5m tranche of a 7m Series A funding round with Debiopharm Innovation Fund SA to scale its in silico clinical trial simulation platform Jink from a consulting to software as a service (SaaS) model, which is compliant with FDA priorities and requirements. Novadiscovery pioneers the use of in silicoclinical trials prior to human drug testing to predict drug efficacy and optimize clinical trail design. Several hundred disease and disease subtype-specific parameters are combined in the company's in silico models that mimic the physiology and co-morbidities of virtual patients.

Knowledge-based in silico modelling of clinical trials holds the potential to predict outcomes and optimise the design of clinical trials with the aim to reduce research & development (R&D) costs and time-to-market of novel drugs. Most recently, Novadiscovery accurately modelled the Phase I outcomes of the FXR agonist EYP001 in healthy and subjects infected with the hepatitis B virus (HBX) in a Phase I study. Furthermore, Jink was used to predict Phase II outcomes of a combination of EYP001 with standard therapy.

The Computational Model integrates 300+ biological variables and 600+ parameters. With seven mechanistic submodels (including the effect of FXR agonist on HBV replication, HBV excretion, bile acid physiology and EYP001, ETV, and pegylated interferon drug models), the model has been used to predict quantitative efficacy of treatments on disease-related endpoints (eg. plasma HBV DNA and HBsAg concentrations) in a virtual population. All the submodels are ultimately combined into a multi-scale Computational Model simulating the dynamics of biological entities at the molecular, cellular and organ levels.

We have seen the significant positive impact our in silico trials platform can have on reducing R&D costs and compressing time-to-market for new drugs and in drug repositioning, stressed Franois-Henri Boissel, CEO and Co-Founder of Nova. This funding allows us to accelerate the development of our platform in a SaaS model that will make it available to a growing number of clients and project, notably in the US. We intend to complete the 7m Series A in 2020.

Reducing R&D costs and time-to-market has become a key strategic objective for healthcare companies and payors. The in silico trial market is evaluated to grow to $2,88bn in annual revenue by 2022, when it will still represent only a small fraction of $165bn annual drug R&D spent.

Reducing number of real patients involved in clinical trials is also a main issue, for both the industry and the regulators. Because they are not so many considering the number of drugs to be evaluated, and their participation in a clinical trial must be as ethical as possible. Novas unique hybrid approach to running in silico clinical trials presents several benefits, one of which being that it can operate in data-poor environments, which is the biggest hurdle more conventional artificial intelligence (AI)-based approaches are facing.

View original post here:
Novadiscovery takes off with 5 Series A financing - European Biotechnology

Published: 16:50 Updated: 17:04 Monday 06 January 2020

A renowned scientist and former Tomorrows World presenter has been announced as one of the keynote speakers at the Industrial Biotechnology Innovation Centre (IBioIC) annual conference next month.

Vivienne Parry will address the event, which is now in its sixth year and expected to attract more than 450 delegates including IB business leaders, policy-makers, investors and innovators and technical experts from around the world. They will congregate in Glasgow on 5 and 6 February, and will see innovative companies exhibiting their smart solutions to a global audience.

Parry, a scientist by training, is the head of engagement at Genomics England and a UK Research and Innovation board member and has extensive writing and broadcasting experience that has inspired a generation of scientists.

She said industrial biotechnology (IB) start-ups need to get out and tell people what they are doing, quickly showing the solution to a problem scientists can sometimes struggle to communicate to policy-makers and the public the significance of what they are doing to save the planet.

READ MORE: Comment: Ever heard of industrial biotechnology? Our future may depend on itREAD MORE: Plans to boost Scotlands bio-revolution secure seed fundingKeep it simple and show the real value in your product and the positive impact it can make to everyday life and the environment. When I listen to someone presenting their concepts, I want them to excite me about the potential of their product in a way that is not hyped, but is really clear.

Mark Bustard, commercial director at IBioIC, said a change in mindset is needed if startups are to capitalise on their innovations. Companies like ScotBio, Cellucomp and Celtic Renewables are all fantastic examples of award-winning organisations who are driving science to generate and make products.

Link:
Former Tomorrows World presenter set to address biotechnology event - The Scotsman

Debut Biotechnology

SAN DIEGO (PRWEB) January 07, 2020

Debut Biotechnology, a UC-Irvine spinout that is advancing scalable cell-free biomanufacturing, today announced that it has closed a $2.6M seed round from leading venture capital firms and angel investors. The oversubscribed round was led by KdT Ventures, with participation from Better Ventures, FTW Ventures, and SpringTide Ventures.

We invested in Debut because the way we produce therapeutics and high value chemicals will dramatically change in the next 10 years as the pharma industry transitions from complex, multi-step batch manufacturing, to a far more cost-effective and efficient continuous manufacturing system, said Cain McClary, Founder and Managing Partner of KdT Ventures. Debut Bio will be at the forefront of this shift, which we believe represents one of the most promising opportunities in pharma.

Debut Bio helps the pharmaceutical and specialty chemical industries manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the companys cell-free platform has the ability to transform low-value bio-renewable materials into high value therapeutics and specialty chemicals.

At our core, we are rethinking industrial biomanufacturing and aiming to produce high value molecules in better ways. Natures enzymes have the ability to create complex natural products, so why reinvent the wheel with chemical synthesis? said Dr. Joshua Britton, CEO and Founder of Debut Biotechnology. Enzyme pathways and evolved proteins hold the key.

Debut Bios enzyme cartridges are sequentially arranged in a manner which mimics pathways found in plants and other organisms. Each cartridge is finely-tuned to provide the ideal temperature, pH, concentration, solvent, and reaction time for each individual step to maximize enzymatic productivity and product titer levels. The platform requires far fewer steps than traditional pharma manufacturing and avoids the use of environmentally harmful chemistry. Importantly, it overcomes many challenges typically associated with relying on cells for biomanufacturing.

Bacteria and yeast have been the workhorses of industrial biomanufacturing for years. Unfortunately, these biofactories have their drawbacks; reaction times can be slow, the product and starting material have difficulty passing through the cell wall, and each cell must be reprogrammed to produce a new molecule, said Dr. Britton. Debut Bio envisions an alternative route.

In Debut Bios system, reactants are passed from one enzyme reactor to another to build in-vitro or cell-free biosynthetic pathways. The companys platform uses a sustainable approach by leveraging advanced enzymes outside of the cell to maximize performance and avoid issues with cell-based systems. The platform technology operates under a continuous manufacturing regime that will provide scale, consistency, and ultimately the ability to produce a biomolecule with the click of a button.

Debut Bio has currently partnered with two large manufacturers to integrate its platform into their existing pipelines. The seed funding will be used to support these integrations, expand business development, double the science team, and create a pilot production system.

Were humbled to have received both support and validation from world class, science-focused investors, said Brady Beauchamp, COO and Co-Founder of Debut Biotechnology. We plan to build on this validation in the coming months with our initial customers in the pharmaceutical manufacturing industry.

This funding comes following an announcement last year that the company spun out of UC Irvine with the exclusive license of two inventions developed by Dr. Joshua Britton and Professor Greg Weiss.

To learn more, please visit: https://debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.

Debut Biotechnology was founded by Joshua Britton, Greg Wess, and Brady Beauchamp and is based in sunny San Diego. To learn more, please visit: https://debutbiotech.com/.

Share article on social media or email:

Read more:
Debut Biotechnology Closes $2.6M Seed Round to Bring Continuous Biomanufacturing of High-Value Molecules to Pharma - PR Web

Therapix Biosciences Ltd - ADR (TRPX) is near the bottom in its industry group according to InvestorsObserver. TRPX gets an overall rating of 4. That means it scores higher than 4 percent of stocks. Therapix Biosciences Ltd - ADR gets a 1 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Therapix Biosciences Ltd - ADR (TRPX) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 4 means the stock is more attractive than 4 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Therapix Biosciences Ltd - ADR (TRPX) stock is lower by -6.25% while the S&P 500 is up 0.09% as of 1:52 PM on Friday, Jan 10. TRPX has fallen -$0.06 from the previous closing price of $0.88 on volume of 71,454 shares. Over the past year the S&P 500 is up 26.22% while TRPX has fallen -77.93%. TRPX lost -$2.40 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Therapix Biosciences Ltd - ADR click here.

View post:
Is Therapix Biosciences Ltd - ADR (TRPX) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

The 38th annual JPMorgan Healthcare Conference, which is tipped off as the biggest health care investment symposium, kicks off Monday in San Francisco, California.

From the high and mighty to the smallest of nanocaps, biopharma and health care companies have scheduled presentations at the four-day event. It's a no-brainer that the presentations will move stocks and serve as key catalysts for respective companies.

BofA Securities analyst Geoff Meacham expects investors to be acutely focused on 2020 expectations and the potential to maintain the positive momentum of 2019's year-end rally. The analyst is bracing for a conservative tone from larger-cap names, given the moderate but improving growth expectations that would offer scope for multiple guidance revisions throughout the year.

Meacham expects discussions at the conference to be focused on value creating themes such as expanding indications, new product cycles, especially with oncology, inflammation & immunology and orphan diseases and advancing innovation in gene/cell therapy.

"Combined with the unlikelihood of near-term major structural reform and P/E ratios that now lag improving expectations, we remain positive on the sector and the outlook for multiple expansion, with greater generalist participation," Meacham wrote in a note this week.

Here's what BofA expects from some key presenters in its coverage universe.

See also: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Bristol-Myers Squibb Co (NYSE: BMY)

Bristol-Myers Squibb, which completed the acquisition of Celgene late last year, is likely to give at least partial guidance. Meacham believes 2020 guidance could be an early positive driver of shares.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

The analyst expects Vertex to provide fourth-quarter update on its cystic fibrosis agent Trikafta, with the analyst expecting sales of $223 million, well above the consensus estimate of $64 million.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

BioMarin could delve on the commercial opportunity of valrox and vosoritide following the filing for the former and positive Phase 3 data for the latter.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Regeneron is likely to release fourth-quarter sales of Eylea. Given Eylea's declining growth, Meacham said the focus could shift to Dupixent, which remains a key P&L driver.

Biogen Inc (NASDAQ: BIIB)

BofA expects Biogen to specify the timing of its aducanumab regulatory filing, if it hasn't been already submitted. The company could also announce a settlement with Mylan NV (NASDAQ: MYL) over the Tecfidera intellectual property right.

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Meacham expects Alexion to focus on its portfolio diversification strategy, especially due to pressure from activists and competitors. Updates on ALXN1830 and anti-Factor D ACH-5228 is likely.

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead is likely to update on its global launch plans for filotinib, with the second half of 2020 being the likely timeframe.

Amgen, Inc. (NASDAQ: AMGN)

Meachem expects Amgen to discuss the integration of Otezla into its I&I franchise, update the status of assets in its oncology pipeline and give its expectations for the launch of its biosimilars.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original post:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations - Benzinga

Vir Biotechnology (VIR) registered volume of 79390 shares on Wednesday trading session as compared to an average volume of 206.92K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. Listed Shares of the Vir Biotechnology (VIR) moved up 2.05% to trade at $12.43 in the last trading session ended on 01/08/2020. It has a market capitalization of $1.38B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock EPS is $-1.26 against its recent stock value of $12.43 per share.

First we will be looking for the boiling points and excitability of Vir Biotechnology (VIR) stock, it purposes common trait for traders and value investors.

Volatility Indicators for Vir Biotechnology:

Volatility of the Vir Biotechnology remained at 4.22% over last week and shows 5.62% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 0.69.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -1.15% during the period of last 5 trading days. The stock maintained for the month at -1.51%. The stock noted year to date 2019 performance at -1.15% . The stock is now standing at -24.67% from 52 week-high and is situated at 6.69% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 45.47.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently down -0.87% from its 20 days moving average and trading -5.32% below the 50 days moving average. The stock price has been seen performing along below drift from its 200 days moving average with -6.63%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Link:
What to Consider on Vir Biotechnology (VIR) Stock? - News Welcome

Palatin Technologies, Inc. (PTN) is near the top in its industry group according to InvestorsObserver. PTN gets an overall rating of 49. That means it scores higher than 49 percent of stocks. Palatin Technologies, Inc. gets a 52 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Palatin Technologies, Inc. (PTN) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 49 means the stock is more attractive than 49 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Palatin Technologies, Inc. (PTN) stock is down -7.31% while the S&P 500 has risen 0.09% as of 1:53 PM on Friday, Jan 10. PTN has fallen -$0.05 from the previous closing price of $0.74 on volume of 1,958,045 shares. Over the past year the S&P 500 is up 26.22% while PTN has fallen -8.00%. PTN earned $0.14 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 4.98.

To screen for more stocks like PTN click here.

Read more:
Is Palatin Technologies, Inc. (PTN) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susans post? Respond in the comments section below.

In all candor, I had no long-term intentions in February 2013 when I started this irregular series tracking biotechnology in countries starting with the letter I. While touching on topical developments for biotech in Iceland, Iran, Ireland, and Italy (Part 3 and Part 11), Israel and India figured prominently due to my direct experience. I first wrote about Israel in February 2013 as the first installment in the series, and have returned to chart ongoing developments (Part 5, Part 8 and Part 12), and India (Part 2, Part 7, Part 10). (Along the way, I also posted a separate 2-part series anticipating changes in policy at the start of the first Modi Administration here and here.)

In retrospect, both Israel and India bear witness to the transformative power of intellectual property (IP) protection for commercial development of biotechnology. So I thought it would be fun to start off the 2020s by taking stock of just how much has changed for innovative life sciences over the last decade, with this additional installment on Israel (and another in the coming weeks on India).

To recap: I first started tracking Israels IP regime in 1994 as a Second Secretary at the Economic Section of the US Embassy. At that time, Teva was Israels largest private employer and had very definite views on Israels implementation of the new WTO Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Suffice it to say, when Teva talked, the Government of Israel listened.Consequently Israel backtracked on early commitments to implement effective marketing exclusivity for pharmaceuticals (TRIPS 39.3 obligations) and also dragged its feet on needed patent law reforms. Throughout my remaining tenure at the State Department, subsequent efforts at PhRMA (Fall 1999 Summer 2005) and beyond, Israel resisted adopting IP reforms needed to promote investment in commercialization of innovative life sciences.

Recognized as the Start-Up Nation for many years, Israel leveraged excellence in basic science for successful commercialization of military, communications and related technologies, and expected similar success in innovative biopharma. Despite longstanding, generous government support for basic research, effective technology transfer, and broader rule of law culture, however, Israel failed to attract meaningful biotech investment.

At the U.S.-Israel Biotechnology Business Roundtable held on the margins of BIO2010 in Chicago, then Chief Scientist Dr. Eli Opper openly expressed frustration at the absence of global biopharma R&D centers and sought advice on how to improve the enabling environment for biopharma. As noted previously, Israel had focused more on direct subsidies and not on needed legal reforms, and participants in the 2010 breakfast meeting repeatedly raised IP as an important barrier to R&D investment. Although it took some time for Israel to commit fully to necessary reforms, Israel ultimately passed IP reforms important for biotechnology in 2014.

Israels implementation of WTO TRIPS data exclusivity and patent reforms provided an important signal to the international innovative industry, precipitating an unprecedented flowering of innovative technologies.

Highlights include:

Whereas Israeli technologies were previously licensed out at early stages due to the inability to fund translational research, Israels innovative life sciences companies are now well represented across the full innovative life cycle, from Seed through Revenue growth.

The bottom line: IATIs Annual Israeli Life Science Industry Report 2019 estimates that approximately 1600 life sciences companies are active in Israel, nearly double the number in existence in 2010. Israels biotech companies are now able to attract both domestic and foreign investment across a range of established and emerging areas of technology, including agrobiotech, digital health, medical cannibis, the microbiome therapeutics, womens health, regenerative medicine, and more.

And in the process Israel has transformed from a poster-child of TRIPS defiance into a real-world demonstration of the critical importance of effective IP for biotechnology commercialization, even in the Start-Up Nation.

What a difference a decade can make.

About the Author:

President of Finston Consulting, LLC since 2005,Susan Kling Finston is a micro-multinational working with innovative companies on biotechnology, trade and development issues, and KOL in commercialization of microbiome technologies as practical tool for human health. In 2006 she founded the Washington Embassy Network (WEN), a forum for informal and collegial information sharing around trade, tech transfer, IP and the environment. She is a contributing blogger at best of the web biotechblog.com. She also has served as a cleared advisor to the Commerce Department and the U.S. Trade Representative (IPR, Tariff/Trade Facilitation).Past Experience: Foreign Service Officer, Department of State, with overseas postings including London, Tel Aviv and Manila (1988 1999); Motions Clerk, Federal Court of Appeals for the Seventh Circuit, Chicago, Illinois (1986 1988). She is admitted to practice before the Illinois Bar, the U.S. Court of Appeals for the Seventh Circuit, and the U.S. Supreme Court. Foreign languages are Hebrew and French.

Continue reading here:
Biotechnology in Countries Starting with "I" - Part 13:... - Biotech Blog

New Jersey, United States, The recent report added by Verified Market Research gives a detailed account of the drivers and restraints in the Nanoparticles in Biotechnology and Pharmaceuticals Market. The research report, titled [Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report 2020] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the global Nanoparticles in Biotechnology and Pharmaceuticals market and the current trends that are likely to shape its future. Primary and secondary research methodologies have been used to put together an exhaustive report on the subject. Analysts have offered unbiased outlook on the global Nanoparticles in Biotechnology and Pharmaceuticals market to guide clients toward a well-informed business decision.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=PJN&utm_medium=005

Top 10 Companies in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Nanoparticles in Biotechnology and Pharmaceuticals Market is segmented on the basis of product type, applications, and its end users.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=PJN&utm_medium=005

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=PJN&utm_medium=005

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

See the rest here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Top Companies, Business Opportunities and Growth 2020 to 2027 - Primo Journal

Global Biotechnology Instrumentation market report

TMR boasts its expertise by collecting 1.2 Mn+ data points every year in its data base. Our dedicated crew of experts are in consistent communication with relevant local distributors, and service providers to gather accurate industry-centric insights. We serve our clients day-and-night and offer reports tailored to the clients needs.

Analysts at TMR, influenced by the potential, have published a report on the global Biotechnology Instrumentation market. As per the report, government support, rising consumption of Biotechnology Instrumentation , and enhanced purchasing capacity of consumers are characterizing the Biotechnology Instrumentation market is expected to grow at a CAGR of xx% over the forecast timeframe 2019-2029.

Reports at discounted rate for early birds!!!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=167

competitive landscape is also included in the report, undertaken with the help of a detailed Porters five forces analysis.

Global Biotechnology Instrumentation Market: Trends and Opportunities

The global biotechnology instrumentation market witnessed significant traction in the past few years owing primarily to the vast rise in demand for biotechnology products for the production of personalized medicine. This emerging area of medicine, which aims to serve consumers through medicines produced by keeping in mind each individuals biological makeup and eliminate the negative effects that could result from mass-produced medicines, is expected to be one of the key consumers of biotechnology products in the next few years.

With the vast rise in the prevalence of a variety of chronic diseases across the globe, the demand for personalized medicines is expected to rise at a significant pace in the next few years. This will also act as a significant growth factor for the global market for biotechnology instrumentation as a rapid surge is expected in the demand for human resources capable of serving the heightened demand for biotechnology products.

The vast rise in the usage of 2D and 3D cell cultures in the field of discovery and manufacture of new drug compounds has also emerged as a key factor boosting the growth of the global biotechnology instrumentation market. A significant rise in research activities surrounding gene expression, especially since the inception of the Human Genome Project, has boosted the global demand for microarrays for studying the expression of genotype or gene clusters, propelling the global biotechnology instrumentation market.

Global Biotechnology Instrumentation Market: Geographical Dynamics

North America and Europe are key markets for biotechnology instrumentation owing to the presence of a large number of some of the worlds largest biotechnology and pharmaceutical companies. The regions are also home to some of the leading universities continuously undertaking research in the field of gene expression, thus leading to vast growth opportunities for the biotechnology instrumentation market. In the next few years as well, these regions are expected to remain at the forefront of the global biotechnology instrumentation market, leading to vast development and growth opportunities for companies wanting to venture into this highly lucrative market.

Developing economies across regions such as Latin America and Asia Pacific are also expected to lead to vast growth opportunities for the market owing to the significant rise in research and development activities in the biotech sector. Research and development arms of several multinational pharmaceutical companies in these regions are also expected to drive the market.

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=167

The Biotechnology Instrumentation market research addresses the following queries:

What information does the Biotechnology Instrumentation market report consists of?

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=167

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.co

Read the original post:
Biotechnology Instrumentation Market's Lead to Remain Unchallenged throughout 2016 2024 - Expert Recorder

The 65 rating InvestorsObserver gives to Amicus Therapeutics, Inc. (FOLD) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, FOLDs 65 overall rating means the stock scores better than 65 percent of all stocks.

Click Here to get the full Stock Score Report on Amicus Therapeutics, Inc. (FOLD) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Amicus Therapeutics, Inc. (FOLD) stock is higher by 0.43% while the S&P 500 has fallen -0.36% as of 9:57 AM on Tuesday, Jan 7. FOLD is higher by $0.04 from the previous closing price of $9.38 on volume of 169,512 shares. Over the past year the S&P 500 is up 26.86% while FOLD has fallen -14.05%. FOLD lost -$1.57 per share the over the last 12 months.

To screen for more stocks like FOLD click here.

Original post:
Is Amicus Therapeutics, Inc. (FOLD) Stock a Good Buy in Biotechnology - InvestorsObserver

Presenting at the Biotech Showcase, 2020 Tuesday, January 14, 2020 10:30 am PST

PhagoMed's presentation at Biotech Showcase will cover its proprietary engineering platform, its lead assets and an outlook to the plans for 2020 and beyond

VIENNA / ACCESSWIRE / January 8, 2020 / PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens in antibiotic resistance and microbiome settings, announced today that its chief executive officer, Alexander Belcredi, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

To view the full release with downloadable visuals and more, click here.

Key Takeaways

About PhagoMed

PhagoMed develops phage-based drug candidates to provide a solution in these settings where antibiotics fail. Phages are natural viruses that infect and kill bacteria. Phages and their proteins (such as lysins) are also highly precise and only target individual bacterial species. PhagoMed has developed a proprietary engineering platform to develop drug-grade phages and lysins. During 2019 the team validated the platform and generated two proprietary drug prototypes in two indications of high medical need: a phage cocktail to treat implant-associated infections and a recombinant endolysin to treat Bacterial Vaginosis and re-stabilize the vaginal microbiome.

Contact:

Alexander BelcrediAlexander.belcredi@phagomed.com+43-676 38 11 082CEO | Business & Finance

SOURCE: Phagomed

View source version on accesswire.com: https://www.accesswire.com/572507/PhagoMed-Biopharma-GmbH-PhagoMed-a-pre-clinical-biotechnology-company-targeting-bacterial-pathogens-announced-today-that-its-Chief-Executive-Officer-Alexander-Belcredi-will-present-at-the-Biotech-Showcase-2020-Conference

Read the rest here:
PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive...

In this Agriculture Biotechnology Market Global Industry Analysis & Forecast to 2030 research report, the central factors driving the advancement of this industry were recorded and the business accessories and end overseers were indulgent. This statistical surveying Agriculture Biotechnology report investigates and inspects the industry and determines a widely inclusive estimate of its development and its details. Another perspective that was efficient is the cost analysis of the prime products driving in the Agriculture Biotechnology Industry remembering the overall revenue of the manufacturers.

The following key Agriculture Biotechnology Market insights and pointers are covered during this report:

Request a demo sample: https://prophecymarketinsights.com/market_insight/Insight/request-sample/2913

The prime manufacturers covered during this report are:

Detail Segmentation:

Global agriculture biotechnology market by type:

Global agriculture biotechnology market by application:

Global agriculture biotechnology market by region:

Download PDF Brochure @ https://prophecymarketinsights.com/market_insight/Insight/request-pdf/2913

The report is an entire guide in providing complete Agriculture Biotechnology processes, cost structures, raw materials, investment feasibility, and investment return analysis. The SWOT analysis, market growth, production, profit, and supply-demand statistics are offered

The historical and future trends, prices, product demand, prospects, and Agriculture Biotechnology marketing channels are stated. The current business and progressions, future methodologies, market entrants are explained. The consumers, distributors, manufacturers, traders, and dealers in Business Intelligence (Bi) Software Market are covered. A comprehensive research methodology, market size estimation, market breakdown, and data triangulation is roofed.

Checkout Complete Details Here: https://prophecymarketinsights.com/market_insight/Global-Agriculture-Biotechnology-Market-By-2913

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Browse Similar Reports:

The rest is here:
Global Agriculture Biotechnology Market Perspective with Study of Leading Players and Revenue to Significant Growth Forecast by 2030 - Primo Journal

Madeleine Dipenaar has already been to the US space agency Nasa in Houston Texas where she met astronauts testing travel to Mars.

South Africa's top matriculant from the class of 2019, Madeleine Dippenaar. Picture: Kayleen Morgan/EWN

JOHANNESBURG - Madeleine Dipenaar from the Northern Cape is the top-performing pupil of 2019.

The young South African woman has already been to the US space agency Nasa in Houston Texas where she met astronauts testing travel to Mars.

Dipenaar is the second of three girls in her home. She said she had been top of her class since grade 8 but she never expected to top the whole country.

I was shocked when I got the call. I thought I could be top 10 provincially but not nationally.

Madeleine was one of two students from South Africa who visited Nasa in 2018 to study a project about human travel to Mars.

Her interest is in biology.

Im going to study molecular biology and biotechnology.

Madeleine said that she had yet to decide what to do with the qualifications she would acquire.

To get your results, visit matric.ewn.co.za

Go here to read the rest:
SAs top matriculant to focus on molecular biology and biotechnology - Eyewitness News

Equities research analysts forecast that BIO-TECHNE Corp (NASDAQ:TECH) will report earnings of $1.14 per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for BIO-TECHNEs earnings. The lowest EPS estimate is $1.12 and the highest is $1.16. BIO-TECHNE reported earnings of $1.06 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.5%. The company is expected to report its next quarterly earnings report on Tuesday, February 4th.

On average, analysts expect that BIO-TECHNE will report full-year earnings of $4.94 per share for the current year, with EPS estimates ranging from $4.85 to $5.04. For the next year, analysts expect that the business will post earnings of $5.77 per share, with EPS estimates ranging from $5.45 to $6.07. Zacks earnings per share averages are an average based on a survey of research analysts that cover BIO-TECHNE.

BIO-TECHNE (NASDAQ:TECH) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.14. The firm had revenue of $183.24 million during the quarter, compared to analysts expectations of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firms revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.98 earnings per share.

Several equities research analysts recently weighed in on TECH shares. TheStreet upgraded BIO-TECHNE from a c+ rating to a b- rating in a research note on Wednesday, November 27th. ValuEngine cut BIO-TECHNE from a buy rating to a hold rating in a research note on Tuesday, December 3rd. BidaskClub upgraded BIO-TECHNE from a sell rating to a hold rating in a research note on Tuesday, September 17th. Zacks Investment Research cut BIO-TECHNE from a hold rating to a sell rating in a research note on Saturday, November 2nd. Finally, Stifel Nicolaus started coverage on BIO-TECHNE in a research note on Thursday, November 14th. They issued a buy rating and a $235.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the companys stock. The stock has an average rating of Hold and a consensus target price of $224.50.

In other BIO-TECHNE news, CEO Charles R. Kummeth sold 703 shares of the businesss stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $222.01, for a total value of $156,073.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Roeland Nusse sold 8,347 shares of the businesss stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $219.33, for a total value of $1,830,747.51. Following the completion of the sale, the director now owns 15,721 shares of the companys stock, valued at approximately $3,448,086.93. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,271 shares of company stock valued at $7,503,700. 4.20% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of BIO-TECHNE by 97.1% during the second quarter. Invesco Ltd. now owns 1,064,196 shares of the biotechnology companys stock worth $221,874,000 after purchasing an additional 524,216 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of BIO-TECHNE by 6,323.4% during the second quarter. Nuveen Asset Management LLC now owns 126,091 shares of the biotechnology companys stock worth $26,289,000 after purchasing an additional 124,128 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of BIO-TECHNE by 229.8% during the second quarter. BNP Paribas Arbitrage SA now owns 47,344 shares of the biotechnology companys stock worth $9,871,000 after purchasing an additional 32,989 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of BIO-TECHNE by 3.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 951,301 shares of the biotechnology companys stock worth $186,141,000 after purchasing an additional 31,700 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of BIO-TECHNE by 20.2% during the third quarter. Candriam Luxembourg S.C.A. now owns 129,857 shares of the biotechnology companys stock worth $25,000 after purchasing an additional 21,840 shares during the last quarter. Institutional investors own 93.11% of the companys stock.

TECH stock traded down $5.29 during trading on Friday, hitting $213.02. 122,699 shares of the companys stock were exchanged, compared to its average volume of 117,811. The business has a 50-day moving average price of $212.32 and a two-hundred day moving average price of $204.52. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of 56.06, a PEG ratio of 4.61 and a beta of 1.23. BIO-TECHNE has a 52-week low of $132.75 and a 52-week high of $222.87. The company has a current ratio of 4.44, a quick ratio of 3.41 and a debt-to-equity ratio of 0.47.

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 22nd. Shareholders of record on Friday, November 8th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date was Thursday, November 7th. BIO-TECHNEs dividend payout ratio is currently 33.68%.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Featured Article: What causes a recession?

Get a free copy of the Zacks research report on BIO-TECHNE (TECH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.

See the rest here:
$1.14 Earnings Per Share Expected for BIO-TECHNE Corp (NASDAQ:TECH) This Quarter - Riverton Roll

We think intelligent long term investing is the way to go. But unfortunately, some companies simply dont succeed. For example, after five long years the Medigen Biotechnology Corp. (GTSM:3176) share price is a whole 62% lower. We certainly feel for shareholders who bought near the top.

View 2 warning signs we detected for Medigen Biotechnology

Medigen Biotechnology wasnt profitable in the last twelve months, it is unlikely well see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesnt make profits, wed generally expect to see good revenue growth. Thats because its hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last half decade, Medigen Biotechnology saw its revenue increase by 5.6% per year. Thats not a very high growth rate considering it doesnt make profits. This lacklustre growth has no doubt fueled the loss of 17% per year, in that time. Wed want to see proof that future revenue growth is likely to be significantly stronger before getting too interested in Medigen Biotechnology. When a stock falls hard like this, some investors like to add the company to a watchlist (in case the business recovers, longer term).

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

Its nice to see that Medigen Biotechnology shareholders have received a total shareholder return of 49% over the last year. Theres no doubt those recent returns are much better than the TSR loss of 17% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, weve discovered 2 warning signs for Medigen Biotechnology (of which 1 is major) which any shareholder or potential investor should be aware of.

But note: Medigen Biotechnology may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on TW exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the original post here:
Introducing Medigen Biotechnology (GTSM:3176), The Stock That Slid 62% In The Last Five Years - Simply Wall St

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). This addition is effective prior to market open today.

The NASDAQ Biotechnology Index tracks the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Selected companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NASDAQ Biotechnology Index is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF. For more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Stoke TherapeuticsStoke Therapeutics, Inc. (Nasdaq:STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The companys lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

Excerpt from:
Stoke Therapeutics Added to NASDAQ Biotechnology Index - Business Wire

Biotechnology is a technological application that uses living organisms, biological systems or derivatives to produce or modify products or processes for specific use. Biotechnology encompasses a wide range of procedures required for modifying living organisms to fulfill various demands for domestic as well as industrial applications. Thus, biotechnology is a general term that is used for a wide range of techniques that are involved in the production, transformation or degradation of the desired product. Biotechnology based chemicals are the products that are manufactured by applying various techniques such as fermentation. Biotechnology based chemicals comprises polyhydroxyalkanoates, lactic acid, lysine, citric acid, glutamic acid and threonine. The technology used in manufacturing biotechnology based chemicals are simple however, the entire production process should be carried out under the supervision of trained personnel. Glutamic acid is the most widely used amino acid manufactured as well as consumed in the world. Biotechnology based chemicals find application in pharmaceuticals, food industry, animal feed and consumer goods manufacturing industries among others.

Pharmaceutical industry is the largest consumer of biotechnology based chemicals. The growing demand for natural medicines than that compared to synthetic chemicals is expected to augment the overall demand for biotechnology based chemicals. In addition, growing awareness of the several side effects associated with the chemical drugs is expected to boost the overall biotechnology based chemicals market. The animal feed industry is also one of the major consumers of biotechnology based chemicals market. The growing demand for lysine in animal feed is expected to boost the overall demand for biotechnology chemicals market. Lactic acid finds applications in a wide range of industries. The growing demand for manufacturing polylactic acid (PLA) plastics boost the demand for lactic acid which in turn is expected to augment the overall biotechnology based chemicals market. However, high cost associated with the manufacturing of biotechnology based chemicals is expected to restrain the overall growth of the market.

The growing demand for pharmaceutical products has expected to augment the overall demand for biotechnology based chemicals in China. China is the largest consumer of biotechnology based chemicals market. The growing demand for citric acid especially from the food and beverage industry in China is expected to augment the overall demand for biotechnology based chemicals market. North America is expected to be the next largest consumer of biotechnology based chemicals owing to the growing consumer preference for natural products. The demand for biotechnology based chemicals is expected to grow rapidly owing to the presence of dominant animal feed and other end use industries in Europe.

Lysine is a crucial ingredient used in the animal feed for swine and poultry feeds. Thus, the growing demand for animal feed is expected to boost the overall demand for biotechnology based chemicals market. Rest of Asia Pacific is expected to experience rapid growth in the demand for biotechnology based chemicals owing to the growing pharmaceutical industry in the region. However, Rest of the World is expected to exhibit sluggish growth in the demand for biotechnology based chemicals in the next few years.

Kemin, BioAmber Inc. and Stora Enso are some of the major participants in the biotechnology based chemicals market. The companys present in the focus mainly towards research as they intend to introduce innovative products in the market.

This post was originally published on Market Research Sheets

Go here to see the original:
Biotechnology Based Chemicals Market Key Players, Industry Overview and Forecast Analysis by 2020 - Market Research Sheets

Puma Biotechnology, Inc. [PBYI] took an upward turn with a change of -1.36%, trading at the price of $8.73 during the trading session on . The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 528911 shares changed hands being bought and sold, while Puma Biotechnology, Inc. shares have an average trading volume of 1.76M shares for that time period. PBYI monthly volatility recorded 10.00%, in the meanwhile having share price volatility for the week set at 8.87%. PS value for PBYI stocks is 1.29 with PB recorded at 20.11.

Its stock price has been found in the range of 6.26 to 43.90. This is compared to its latest closing price of $8.85.

Keep on the lookout for this organizations next scheduled financial results, which are expected to be made public on Thu 27 Feb (In 62 Days).

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology, Inc. [PBYI] sitting at -37.72 and its Gross Margin at +86.21, this companys Net Margin is now -33.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -65.75, and its Return on Invested Capital has reached -55.70%. Its Return on Equity is -259.28, and its Return on Assets is -53.49. These metrics suggest that this Puma Biotechnology, Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology, Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 442.74. Similarly, its Total Debt to Total

What about valuation? This companys Enterprise Value to EBITDA is -3.71. The Enterprise Value to Sales for this firm is now 1.15, and its Total Debt to Enterprise Value stands at 0.20. Puma Biotechnology, Inc. [PBYI] has a Price to Book Ratio of 22.73.

Shifting the focus to workforce efficiency, Puma Biotechnology, Inc. [PBYI] earns $922,761 for each employee under its payroll. Similarly, this companys Receivables Turnover is 15.88 and its Total Asset Turnover is 1.18. This publicly-traded organizations liquidity data is also interesting: its Quick Ratio is 2.99 and its Current Ratio is 3.02. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Puma Biotechnology, Inc. [PBYI] has 40.85M shares outstanding, amounting to a total market cap of $361.52M. Its stock price has been found in the range of 6.26 to 43.90. At its current price, it has moved down by -80.11% from its 52-week high, and it has moved up 39.46% from its 52-week low.

This stocks Beta value is currently 1.64, which indicates that it is 8.87% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 50.71. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology, Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

See the article here:
Puma Biotechnology, Inc. [PBYI] could give the highest percentage gains? Check Out this Analysis - The Dwinnex

NEW YORK, Dec. 23, 2019 /PRNewswire/ --

The global liquid handling technology market is expected to reach US$ 5,705.63 Mn in 2027 from US$ 3,201.36 Mn in 2018. The market is estimated to grow with a CAGR of 6.7% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05833605/?utm_source=PRN

The key factors that are driving the growth of liquid handling technology market are increasing drug discovery activities, growing biopharmaceutical industry and rising research and development expenses. Whereas, the market is expected to have slow growth due to the scarcity of skilled professionals during the forecast period.In the past few years, the biopharmaceutical industry has experienced exponential growth and is growing in the developing region at an extraordinary pace.The North American region owe highly advanced techniques that enable it to offers more of the biotechnology products in the market.

Regions such as Europe and the Asia Pacific have speeded up their investments and interest in the field of biotechnology, whereas regions such as South and Central America and the Middle East are developing their biotechnology industry significantly.Developed regions are consolidated with various market leaders and are experiencing a rising number of start-up biotechnology companies.The developing regions are collaborating with various market leaders and government entities to expand research and development activities in the biotechnology sector.

For instance, North American and European biotechnology sectors are heading towards the Asia Pacific region due to increased clinical activities. Since 2016, in the Asia Pacific, there are has been an increase in clinical activities from the biotech companies approximately by 26%.The biotechnology industry is also experiencing rising initiatives by the government and private bodies. For instance, in September 2017, the U.S.-Ukraine Foundation has launched a new biotechnology initiative to support the developments in the field of biotechnology, which resulted in the exertion to build new networking opportunities. Also, the U.S.-Ukraine Foundation has become a member of the Biotechnology Innovation Organization (BIO) and is the global leader of the trade association representing biotechnology companies, state biotechnology centers, academic institutions, and related organizations across the United States and more than 30 other nations.Thus, owing to the rise in biotechnology sector, increasing initiatives and growing clinical activities in the biotechnology industry are likely to increase the growth of the liquid handling technology market during the forecast period.The liquid handling technology market is segmented on the basis of product, type, application and end user.The market based on product segment is classified as automated workstations, small devices, consumables.

On the basis of type the market is classified as automated liquid handling, manual liquid handling, and semi-automated liquid handling. Based on the application segment market is divided into drug discovery & ADME-Tox Research, cancer and genomic research, bioprocessing/biotechnology. Based on end user the market is categorized as pharmaceutical and biotechnology companies, contract research organization, academic and research institutes

Read the full report: https://www.reportlinker.com/p05833605/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-liquid-handling-technology-market-is-expected-to-reach-us-5-705-63-mn-in-2027-from-us-3-201-36-mn-in-2018--300979003.html

SOURCE Reportlinker

Visit link:
The global liquid handling technology market is expected to reach US$ 5705.63 Mn in 2027 from US$ 3201.36 Mn in 2018 - P&T Community